Trial V1

The chart shows the growth of an initial investment of $10,000 in Trial V1, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced Every year.

Based on dividend-adjusted daily data since Aug 30, 2022, Trial V1's average daily return is +0.12%, while the average monthly return is +2.39%. At this rate, an investment would double in approximately 2.4 years.

Historically, 66% of months were positive and 34% were negative. The best month was Apr 2026 with a return of +21.2%, while the worst month was Sep 2022 at -8.1%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 3 months.

On a daily basis, Trial V1 closed higher 57% of trading days. The best single day was Apr 9, 2025 with a return of +10.1%, while the worst single day was Jun 5, 2026 at -9.4%.

Trial V1 has an annualized alpha of 10.52%, beta of 1.13, and R2 of 0.81 versus S&P 500 Index. Calculated based on daily prices since August 30, 2022.

• This portfolio captured 145.20% of S&P 500 Index gains but only 92.68% of its losses - a favorable profile for investors.
• This portfolio generated an annualized alpha of 10.52% versus S&P 500 Index - delivering returns beyond what market exposure alone would predict.
• With beta of 1.13 and R2 of 0.81, this portfolio moves broadly in line with S&P 500 Index - much of its variation is explained by market exposure rather than independent behavior.

Trial V1 has an expense ratio of 0.25%, which is considered low. Below, you can find the expense ratios of the portfolio's funds side by side and easily compare their relative costs.

Trial V1 ranks 76 for risk / return — better than 76% of Portfolios on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below presents risk-adjusted performance metrics for Trial V1 and compares them with S&P 500 Index.

The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Trial V1 Sharpe ratios as of Jun 9, 2026 (values are recalculated daily):

• 1-Year: 2.39
• All Time: 1.58

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

Compared to the broad market, where average Sharpe ratios range from 1.59 to 2.46, this portfolio's current Sharpe ratio falls between the 25th and 75th percentiles. This indicates that its risk-adjusted performance is in line with the majority of portfolios, suggesting a balanced approach to risk and return—likely suitable for a wide range of investors.

The chart below shows the rolling Sharpe ratio of Trial V1 compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.

Trial V1 provided a 2.75% dividend yield over the last twelve months.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Trial V1. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Trial V1 was 17.59%, occurring on Apr 8, 2025. Recovery took 38 trading sessions.

The current Trial V1 drawdown is 7.74%.

The chart below shows the rolling one-month volatility.